Company Insights

CLPT customer relationships

Explore interactive graphBrowse insights index
CLPT customer relationship map

ClearPoint Neuro (CLPT): Customer relationships that shape recurring revenue and clinical relevance

ClearPoint Neuro sells an integrated surgical navigation platform — hardware, disposables and menu-driven software — and monetizes through capital equipment sales, annual maintenance/subscription fees, and consulting services to biologics and drug-delivery partners. The company complements equipment placements with loaned systems for pilot evaluations and contracts that bundle upgrades and support, creating a mix of upfront capital receipts and recurring annuity-style revenue. For a concise view of relationship-level intelligence and sourcing, visit https://nullexposure.com/.

How ClearPoint actually earns and what that means for investors

ClearPoint is a commercial-stage medical device company that operates as a seller of capital equipment and provider of tied services. Revenue streams split into: (1) equipment and disposable sales, (2) annual subscription/maintenance contracts that bundle software and hardware upgrades, and (3) professional services and protocol consultation for pharmaceutical partners. The company invoices capital equipment and some service fees at shipment or contract inception, while bundled annual agreements drive recurring cash flows. The installed base — over 90 centers globally — supports consumable sales and upgrade contracts, although operations and revenue are predominantly U.S.-based. The company has disclosed that partners in biologics and drug delivery accounted for approximately 17% of that revenue in 2024, indicating material dependence on pharma collaborations.

Key operating signals investors should track include short-term contract tenors for many service elements, a meaningful subscription component to the commercial offering, and the strategic use of loaned systems for pilots that convert into paid placements. These are company-level indicators of concentration, customer stickiness, and the recurring nature of future revenue.

Why the partner roster matters for valuation and execution

ClearPoint’s customers are not just hospitals; they include gene-therapy and biologics developers that require highly reproducible delivery workflows. That partnership profile creates revenue leverage beyond initial hardware sales — consumables and consulting tied to clinical programs generate follow-on revenue and raise the commercial value of each installed site. Conversely, concentration in biotech partners and dependence on pilot-to-commercial conversions create execution risk: converting loaned systems into long-term paid contracts is essential to unlock recurring margins.

For ongoing relationship monitoring and primary-source clarity, see https://nullexposure.com/.

Customer relationships: who ClearPoint works with (what the public record shows)

Below are the relationships surfaced in the public reporting set, each with a short plain-English summary and the source.

  • PTC Therapeutics (PTCT)
    ClearPoint’s SmartFlow Neuro Cannula is identified for intraputaminal administration of PTC Therapeutics’ gene therapy KEBILIDI, linking ClearPoint devices to a commercial gene-therapy delivery use-case. According to an Accesswire release describing FDA De Novo authorization (reported March 9, 2026), the cannula is intended for that specific therapeutic delivery. Source: company/news release on Accesswire (Mar 2026).

  • BlackRock (BLK)
    BlackRock is listed among ClearPoint’s "existing partners" mentioned on a Q3 2025 earnings call transcript, indicating institutional or partnership visibility in ClearPoint’s update of partner progress; the transcript cites BlackRock alongside other collaborators. Source: Q3 2025 earnings call transcript published on InsiderMonkey (FY2025).

  • uniQure (QURE)
    uniQure is named on the same Q3 2025 earnings call transcript as an active partner updating patients and investors on clinical progress, underscoring ClearPoint’s role in supporting gene-delivery workflows for established gene-therapy sponsors. Source: Q3 2025 earnings call transcript published on InsiderMonkey (FY2025).

  • AskBio
    AskBio appears in the Q3 2025 earnings call transcript among ClearPoint’s partners and is listed as having provided updates on patient programs, signaling an operational relationship in drug-delivery or clinical workflow support. Source: Q3 2025 earnings call transcript published on InsiderMonkey (FY2025).

  • Aona
    Aona is also cited on ClearPoint’s Q3 2025 earnings call transcript as one of the partners that updated stakeholders on progress, reflecting ClearPoint’s engagement with niche therapy developers and clinical programs. Source: Q3 2025 earnings call transcript published on InsiderMonkey (FY2025).

Operating constraints and company-level signals investors must factor

Treat the following as firm-level characteristics that shape revenue predictability, not as attributes of any single customer:

  • Contracting posture — seller with bundled agreements. ClearPoint bills upon shipment for equipment and often at contract inception for certain services; bundled annual fees cover maintenance and upgrade access. This structure yields a mix of upfront cash and recurring recognition that smooths revenue if installed-base growth sustains.
  • Contract tenor — short-term and subscription components. The company discloses contracts with terms typically ranging from one to three years, and a meaningful subscription/annual-maintenance element that supports predictability but requires regular renewal.
  • Geography — global footprint with U.S. concentration. Products are in commercial use globally and installed at more than 90 centers, yet operations and revenues are predominantly U.S.-derived, exposing the business to U.S. reimbursement and hospital procurement cycles.
  • Segment mix — hardware-led with software and services attachment. The ClearPoint system is hardware-centric but the value capture increasingly comes from software upgrades, disposables and consulting services for biologics sponsors.
  • Relationship maturation — pilot-heavy funnel. Loaned systems deployed on an evaluation basis are a structured route to paid placements; pilot-to-purchase conversion rates are a key execution metric.
  • Materiality — pharma/biologics exposure. Biologics and drug-delivery partnerships comprised roughly 17% of that revenue class in 2024, highlighting both strategic upside (large program spend) and concentration risk.

What investors should watch next

  • Pilot conversion rates and renewals for loaned systems, which drive installed-base expansion and recurring revenues.
  • Timing of upgrade/subscription renewals and how the company recognizes contract liabilities tied to annual fees.
  • Revenue mix trends between one-time equipment sales and recurring service/subscription revenue; accelerating annuity share improves valuation multiples.
  • Partner program milestones for named collaborators (PTC, uniQure, AskBio, Aona) because clinical progress translates directly into consumable and service demand.

For more detailed, relationship-level monitoring and source-backed alerts, visit https://nullexposure.com/.

Bottom line

ClearPoint’s commercial model couples capital equipment placements with recurring software, upgrade and services revenue — a structure that creates durable per-site economics if pilots convert and subscription renewals hold. Investor focus should be on pilot conversion, subscription renewal cadence, and the degree to which biotech partner programs generate repeat consumable and consulting spend. For a centralized source of the relationship signals cited in this note, and to track future disclosures, see https://nullexposure.com/.